The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Moxidectin active against an agent of river blindness
FDA has indicated Moxidectin from Medicines Development for Global Health to treat onchocerciasis (river blindness) resulting from Onchocerca volvulus in patients aged 12 years and older. The drug won that indication in June 2020. The drug is the first novel treatment for river blindness in two decades. The anthelmintic drug also has veterinary applications. It is…